FIELD: medicine.
SUBSTANCE: group of inventions refers to the field of medicine, namely to variants of hemostatic agents in the form of a powder based on natural sodium alginate polysaccharide. In one embodiment, said agent comprises a mixture of sodium alginate and fibrin monomer in weight ratios (1–3):(3:1), respectively, and in another variant – a mixture of sodium alginate, fibrin-monomer and thrombin 150–900 units activity of NIH in weight ratios, (3–5):(3–5):(1–5) respectively.
EFFECT: group of inventions ensures the product-line expansion of hemostatic agents with pronounced hemostatic action, as well as good adhesion to the wound and simple manufacturing techniques.
2 cl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
HEMOSTATIC SOLUTION BASED ON SULFUSATED POLYSACCHARIDES AND THE HEMOSTATIC SPONGES PRODUCTION FROM THIS SOLUTION (OPTIONS) | 2017 |
|
RU2652270C1 |
HEMOSTATIC SPONGE AND METHOD OF ITS PRODUCTION | 2016 |
|
RU2628809C1 |
WOUND COVER WITH HEMOSTATIC ACTION, AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2624242C1 |
HAEMOSTATIC AGENT BASED ON POLYVINYLPYRROLIDONE AND METHODS FOR PREPARING ITS PHARMACOLOGICAL FORMS | 2018 |
|
RU2705812C1 |
HAEMOSTATIC GLUE POWDER | 2005 |
|
RU2304440C2 |
HAEMOSTATIC SPONGE AND METHOD FOR ITS PREPARATION | 2016 |
|
RU2618896C1 |
HEMOSTATIC SPONGE (VERSIONS) | 2016 |
|
RU2627855C1 |
HEMOSTATIC COATING IN FORM OF SPONGE OR FILM (VERSIONS) | 2016 |
|
RU2639379C1 |
HAEMOSTATIC AGENT | 2004 |
|
RU2275201C2 |
HEMOSTATIC GLUE | 2004 |
|
RU2270016C2 |
Authors
Dates
2018-07-06—Published
2017-07-12—Filed